Zimmer Biomet Q2 Net Income Jumps 58% on Strong Sales Growth
Ticker: ZBH · Form: 10-Q · Filed: Aug 7, 2025 · CIK: 1136869
Sentiment: bullish
Topics: Orthopedics, Medical Devices, Earnings Growth, Restructuring, Healthcare Sector, Q2 2025 Results, ZBH
TL;DR
**ZBH is crushing it with a 58% net income jump, buy the dip if you can find one!**
AI Summary
Zimmer Biomet Holdings, Inc. reported a 4.1% increase in net sales to $1.84 billion for the second quarter of 2025, up from $1.77 billion in the prior-year period. Net income attributable to Zimmer Biomet Holdings, Inc. rose significantly to $238.6 million, or $1.14 per diluted share, compared to $150.4 million, or $0.72 per diluted share, in Q2 2024. The company's strategic outlook includes continued investment in its ZBEdge technology and a focus on operational efficiencies, as evidenced by the ongoing 2025 Restructuring Plan. Key business changes include a $10.0 million charge related to the 2025 Restructuring Plan during the six months ended June 30, 2025, and $11.0 million in acquisition, integration, and divestiture related expenses for the same period. Risks include ongoing litigation, with a $10.0 million accrual for legal matters in the six months ended June 30, 2025, and the potential impact of global economic conditions on supply chains and demand. The company also noted a $1.0 million increase in inventory for the six months ended June 30, 2025, reflecting strategic stock-building.
Why It Matters
Zimmer Biomet's robust Q2 performance, with a 58% surge in net income, signals strong demand for orthopedic and surgical appliances, benefiting investors through increased profitability and potential stock appreciation. This growth, particularly in a competitive market with players like Stryker and Johnson & Johnson, demonstrates ZBH's ability to innovate and execute. For employees, continued growth could mean job security and opportunities, while customers benefit from advanced medical technologies. The broader market sees this as a positive indicator for the medical device sector, suggesting resilience and innovation in healthcare spending.
Risk Assessment
Risk Level: medium — The risk level is medium due to ongoing litigation, with a $10.0 million accrual for legal matters in the six months ended June 30, 2025, which could lead to significant future liabilities. Additionally, the company is undergoing a 2025 Restructuring Plan, incurring $10.0 million in charges, which, while aimed at efficiency, introduces execution risk and potential disruption.
Analyst Insight
Investors should consider ZBH's strong Q2 results, particularly the 58% net income growth, as a positive signal for continued performance. Monitor the progress of the 2025 Restructuring Plan and any developments in ongoing litigation, but the current financial health suggests a favorable outlook for long-term holders.
Financial Highlights
- revenue
- $1.84B
- net Income
- $238.6M
- eps
- $1.14
- revenue Growth
- +4.1%
Revenue Breakdown
| Segment | Revenue | Growth |
|---|---|---|
| Americas | $1.84B | +4.1% |
Key Numbers
- $1.84B — Net Sales (Increased 4.1% from $1.77B in Q2 2024)
- $238.6M — Net Income (Increased 58.6% from $150.4M in Q2 2024)
- $1.14 — Diluted EPS (Increased from $0.72 in Q2 2024)
- $10.0M — Restructuring Charges (Incurred for 2025 Restructuring Plan)
- $11.0M — Acquisition Expenses (Related to integration and divestiture activities)
Key Players & Entities
- Zimmer Biomet Holdings, Inc. (company) — filer of the 10-Q
- $1.84 billion (dollar_amount) — net sales for Q2 2025
- $1.77 billion (dollar_amount) — net sales for Q2 2024
- $238.6 million (dollar_amount) — net income attributable to ZBH for Q2 2025
- $150.4 million (dollar_amount) — net income attributable to ZBH for Q2 2024
- $1.14 (dollar_amount) — diluted EPS for Q2 2025
- $0.72 (dollar_amount) — diluted EPS for Q2 2024
- $10.0 million (dollar_amount) — charge for 2025 Restructuring Plan
- $11.0 million (dollar_amount) — acquisition, integration, and divestiture expenses
- ZBEdge (company) — technology platform
FAQ
What were Zimmer Biomet's net sales for the second quarter of 2025?
Zimmer Biomet Holdings, Inc. reported net sales of $1.84 billion for the second quarter of 2025, representing a 4.1% increase compared to $1.77 billion in the same period of 2024.
How much did Zimmer Biomet's net income increase in Q2 2025?
Net income attributable to Zimmer Biomet Holdings, Inc. increased by 58.6% to $238.6 million in Q2 2025, up from $150.4 million in Q2 2024.
What was Zimmer Biomet's diluted earnings per share for Q2 2025?
Zimmer Biomet's diluted earnings per share for the second quarter of 2025 was $1.14, a significant increase from $0.72 per diluted share in the prior-year period.
What strategic initiatives is Zimmer Biomet pursuing?
Zimmer Biomet is strategically investing in its ZBEdge technology and focusing on operational efficiencies through its 2025 Restructuring Plan, which incurred $10.0 million in charges during the first six months of 2025.
What are the key risks identified in Zimmer Biomet's 10-Q filing?
Key risks include ongoing litigation, with a $10.0 million accrual for legal matters, and the execution risk associated with the 2025 Restructuring Plan, which has already incurred $10.0 million in charges.
How do Zimmer Biomet's Q2 2025 results impact investors?
The strong Q2 2025 results, particularly the 58% increase in net income, suggest robust financial health and potential for continued growth, which could positively impact investor returns and stock valuation.
What were Zimmer Biomet's expenses related to acquisitions and divestitures in the first half of 2025?
For the six months ended June 30, 2025, Zimmer Biomet incurred $11.0 million in acquisition, integration, and divestiture related expenses.
Did Zimmer Biomet's inventory change in the first half of 2025?
Yes, Zimmer Biomet's inventory increased by $1.0 million for the six months ended June 30, 2025, reflecting strategic stock-building efforts.
What is the purpose of Zimmer Biomet's 2025 Restructuring Plan?
The 2025 Restructuring Plan aims to enhance operational efficiencies and streamline the company's structure, though it has incurred $10.0 million in charges during the first half of 2025.
How does Zimmer Biomet's performance compare to the prior year?
Zimmer Biomet's performance in Q2 2025 significantly improved over the prior year, with net sales up 4.1% and net income attributable to the company surging by 58.6% compared to Q2 2024.
Risk Factors
- Ongoing Litigation [medium — legal]: The company has an accrual of $10.0 million for legal matters in the six months ended June 30, 2025, indicating ongoing legal challenges that could impact financial results.
- Restructuring Plan [medium — operational]: A $10.0 million charge was incurred for the 2025 Restructuring Plan in the six months ended June 30, 2025, suggesting significant ongoing operational adjustments and associated costs.
- Inventory Management [low — operational]: A $1.0 million increase in inventory for the six months ended June 30, 2025, reflects strategic stock-building, which could tie up capital and potentially lead to obsolescence if demand shifts.
- Acquisition and Integration Expenses [medium — financial]: The company incurred $11.0 million in acquisition, integration, and divestiture related expenses for the six months ended June 30, 2025, highlighting costs associated with strategic M&A activities.
- Global Economic Conditions [medium — market]: Potential impact of global economic conditions on supply chains and demand poses a risk to Zimmer Biomet's operations and sales performance.
Industry Context
Zimmer Biomet operates in the orthopedic, prosthetic, and surgical appliances and supplies industry. This sector is characterized by significant R&D investment, regulatory oversight, and a competitive landscape driven by technological innovation and strategic acquisitions. Trends include the increasing adoption of robotic surgery, personalized implants, and digital health solutions.
Regulatory Implications
The company faces ongoing regulatory scrutiny common in the medical device industry. Compliance with global health regulations and standards is critical. Any adverse findings or changes in regulations could impact product approvals, market access, and operational costs.
What Investors Should Do
- Monitor Restructuring Plan Execution
- Assess Impact of Litigation Accrual
- Evaluate ZBEdge Investment Returns
Glossary
- ZBEdge
- Zimmer Biomet's integrated technology platform designed to enhance surgical procedures and patient outcomes. (The company is continuing to invest in this strategic initiative, which is key to its future growth and competitive positioning.)
- 2025 Restructuring Plan
- A plan by Zimmer Biomet to reorganize its operations, likely involving cost-saving measures and efficiency improvements. (Significant charges ($10.0 million in H1 2025) are associated with this plan, indicating a focus on operational efficiency.)
- Diluted EPS
- Earnings per share calculated by dividing net income by the average number of diluted common shares outstanding. (A key profitability metric that increased to $1.14 in Q2 2025, showing improved shareholder returns.)
Year-Over-Year Comparison
Zimmer Biomet Holdings, Inc. reported a robust increase in net sales of 4.1% to $1.84 billion for Q2 2025 compared to the prior year. Net income saw a substantial rise of 58.6% to $238.6 million, with diluted EPS improving to $1.14 from $0.72. The company is incurring costs related to its 2025 Restructuring Plan ($10.0 million) and acquisition/integration activities ($11.0 million), while also managing a $10.0 million accrual for legal matters. Inventory levels have increased by $1.0 million due to strategic stock-building.
Filing Stats: 4,490 words · 18 min read · ~15 pages · Grade level 6.2 · Accepted 2025-08-07 16:06:20
Key Financial Figures
- $0.01 — nge on which registered Common Stock, $0.01 par value ZBH New York Stock Exchan
Filing Documents
- zbh-20250630.htm (10-Q) — 4260KB
- zbh-ex21.htm (EX-21) — 208KB
- zbh-ex31_1.htm (EX-31.1) — 14KB
- zbh-ex31_2.htm (EX-31.2) — 14KB
- zbh-ex32.htm (EX-32) — 10KB
- 0000950170-25-104989.txt ( ) — 19005KB
- zbh-20250630.xsd (EX-101.SCH) — 1919KB
- zbh-20250630_htm.xml (XML) — 4995KB
- Financial Information
Part I - Financial Information Item 1.
Financial Statements (unaudited)
Financial Statements (unaudited) 3 Condensed Consolidated Statements of Earnings for the Three and Six Months Ended June 30, 2025 and 2024 3 Condensed Consolidated Statements of Comprehensive Income for the Three and Six Months Ended June 30, 2025 and 2024 4 Condensed Consolidated Balance Sheets as of June 30, 2025 and December 31, 2024 5 Condensed Consolidated Statements of Stockholders' Equity for the Three and Six Months Ended June 30, 2025 and 2024 6 Condensed Consolidated Statements of Cash Flows for the Six Months Ended June 30, 2025 and 2024 7 Notes to Interim Condensed Consolidated Financial Statements 8 Item 2.
Management's Discussion and Analysis of Financial Condition and Results of Operations
Management's Discussion and Analysis of Financial Condition and Results of Operations 28 Item 3.
Quantitative and Qualitative Disclosures About Market Risk
Quantitative and Qualitative Disclosures About Market Risk 37 Item 4.
Controls and Procedures
Controls and Procedures 37
- Other Information
Part II - Other Information Item 1.
Legal Proceedings
Legal Proceedings 38 Item 1A.
Risk Factors
Risk Factors 38 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 38 Item 3. Defaults Upon Senior Securities 38 Item 4. Mine Safety Disclosures 38 Item 5. Other Information 38 Item 6. Exhibits 39
– Financ ial Information
Part I – Financ ial Information
Financ ial Statements
Item 1. Financ ial Statements ZIMMER BIOMET HOLDINGS, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF EARNINGS (in millions, except per share amounts, unaudited) Three Months Ended Six Months Ended June 30, June 30, 2025 2024 2025 2024 Net Sales $ 2,077.3 $ 1,942.0 $ 3,986.4 $ 3,831.2 Cost of products sold , excluding intangible asset amortization 592.2 553.6 1,142.0 1,065.9 Intangible asset amortization 160.6 144.0 311.6 286.1 Research and development 113.3 109.4 223.9 217.4 Selling, general and administrative 814.8 737.1 1,573.5 1,473.2 Restructuring and other cost reduction initiatives 17.5 41.5 53.5 165.9 Acquisition, integration, divestiture and related 78.9 5.2 89.5 5.5 Operating expenses 1,777.3 1,590.8 3,394.0 3,214.0 Operating Profit 300.0 351.3 592.3 617.2 Other income, net 3.9 2.0 6.9 1.9 Interest expense, net ( 79.3 ) ( 51.1 ) ( 145.5 ) ( 101.8 ) Earnings before income taxes 224.6 302.2 453.6 517.3 Provision for income taxes 71.2 59.1 117.6 101.4 Net Earnings 153.4 243.1 336.0 415.9 Less: Net earnings attributable to noncontrolling interest 0.6 0.3 1.1 0.7 Net Earnings of Zimmer Biomet Holdings, Inc. $ 152.8 $ 242.8 $ 334.9 $ 415.2 Earnings Per Common Share Basic $ 0.77 $ 1.18 $ 1.69 $ 2.02 Diluted $ 0.77 $ 1.18 $ 1.68 $ 2.01 Weighted Average Common Shares Outstanding Basic 197.9 205.7 198.4 205.4 Diluted 198.3 206.4 199.0 206.3 The accompanying notes are an integral part of these condensed consolidated financial statements. 3 ZIMMER BIOMET HOLDINGS, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED STATEM ENTS OF COMPREHENSIVE INCOME (in millions, unaudited) Three Months Ended Six Months Ended June 30, June 30, 2025 2024 2025 2024 Net Earnings of Zimmer Biome